CN113164530A - 粪肠球菌的用途 - Google Patents
粪肠球菌的用途 Download PDFInfo
- Publication number
- CN113164530A CN113164530A CN201880099068.6A CN201880099068A CN113164530A CN 113164530 A CN113164530 A CN 113164530A CN 201880099068 A CN201880099068 A CN 201880099068A CN 113164530 A CN113164530 A CN 113164530A
- Authority
- CN
- China
- Prior art keywords
- disease
- enterococcus faecalis
- diabetic
- metabolic syndrome
- cfu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000194032 Enterococcus faecalis Species 0.000 title claims abstract description 120
- 229940032049 enterococcus faecalis Drugs 0.000 title claims abstract description 119
- 208000001145 Metabolic Syndrome Diseases 0.000 claims abstract description 28
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims abstract description 28
- 239000003814 drug Substances 0.000 claims abstract description 18
- 235000013305 food Nutrition 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims abstract description 10
- 230000002265 prevention Effects 0.000 claims abstract description 10
- 239000002778 food additive Substances 0.000 claims abstract description 8
- 235000013373 food additive Nutrition 0.000 claims abstract description 8
- 238000004519 manufacturing process Methods 0.000 claims abstract description 6
- 208000008589 Obesity Diseases 0.000 claims description 30
- 235000020824 obesity Nutrition 0.000 claims description 30
- 206010012601 diabetes mellitus Diseases 0.000 claims description 25
- 239000006041 probiotic Substances 0.000 claims description 16
- 235000018291 probiotics Nutrition 0.000 claims description 16
- 208000004930 Fatty Liver Diseases 0.000 claims description 15
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 208000010706 fatty liver disease Diseases 0.000 claims description 15
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 15
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 13
- 230000037149 energy metabolism Effects 0.000 claims description 13
- 208000030159 metabolic disease Diseases 0.000 claims description 13
- 230000000529 probiotic effect Effects 0.000 claims description 12
- 208000028389 Nerve injury Diseases 0.000 claims description 11
- 230000008764 nerve damage Effects 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 9
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 8
- 208000016097 disease of metabolism Diseases 0.000 claims description 7
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 7
- 230000036541 health Effects 0.000 claims description 7
- 201000010053 Alcoholic Cardiomyopathy Diseases 0.000 claims description 6
- 208000024827 Alzheimer disease Diseases 0.000 claims description 6
- 206010007637 Cardiomyopathy alcoholic Diseases 0.000 claims description 6
- 206010063547 Diabetic macroangiopathy Diseases 0.000 claims description 6
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 6
- 206010015150 Erythema Diseases 0.000 claims description 6
- 206010018404 Glucagonoma Diseases 0.000 claims description 6
- 208000018737 Parkinson disease Diseases 0.000 claims description 6
- 206010061481 Renal injury Diseases 0.000 claims description 6
- 208000027418 Wounds and injury Diseases 0.000 claims description 6
- 208000029078 coronary artery disease Diseases 0.000 claims description 6
- 230000006378 damage Effects 0.000 claims description 6
- 231100000321 erythema Toxicity 0.000 claims description 6
- 208000018578 heart valve disease Diseases 0.000 claims description 6
- 208000015210 hypertensive heart disease Diseases 0.000 claims description 6
- 208000014674 injury Diseases 0.000 claims description 6
- 208000037806 kidney injury Diseases 0.000 claims description 6
- 230000002956 necrotizing effect Effects 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 238000010521 absorption reaction Methods 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 238000013268 sustained release Methods 0.000 claims description 2
- 239000012730 sustained-release form Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 230000006872 improvement Effects 0.000 abstract description 2
- 239000002417 nutraceutical Substances 0.000 abstract 1
- 235000021436 nutraceutical agent Nutrition 0.000 abstract 1
- 241000194033 Enterococcus Species 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 15
- 241000194031 Enterococcus faecium Species 0.000 description 14
- 238000013218 HFD mouse model Methods 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 8
- 241001468179 Enterococcus avium Species 0.000 description 6
- 241001522957 Enterococcus casseliflavus Species 0.000 description 6
- 230000036760 body temperature Effects 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 230000036528 appetite Effects 0.000 description 5
- 235000019789 appetite Nutrition 0.000 description 5
- 238000002595 magnetic resonance imaging Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 241000194029 Enterococcus hirae Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 241000520130 Enterococcus durans Species 0.000 description 3
- 241000194030 Enterococcus gallinarum Species 0.000 description 3
- 241000178338 Enterococcus pseudoavium Species 0.000 description 3
- 241001235138 Enterococcus raffinosus Species 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 241001191101 Euphorbia mundii Species 0.000 description 3
- 210000003486 adipose tissue brown Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 230000036284 oxygen consumption Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 241001609975 Enterococcaceae Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 235000019577 caloric intake Nutrition 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- SFAYBQDGCKZKMH-UHFFFAOYSA-N BNCC Chemical compound BNCC SFAYBQDGCKZKMH-UHFFFAOYSA-N 0.000 description 1
- 108010062877 Bacteriocins Proteins 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical group CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 1
- 241000520134 Enterococcus mundtii Species 0.000 description 1
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 description 1
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 1
- 108010019598 Liraglutide Proteins 0.000 description 1
- 208000037196 Medullary thyroid carcinoma Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000007683 Pediatric Obesity Diseases 0.000 description 1
- 206010041969 Steatorrhoea Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000021316 daily nutritional intake Nutrition 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 238000013224 high-fat diet-induced obese mouse Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229960002701 liraglutide Drugs 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 238000013116 obese mouse model Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 208000001162 steatorrhea Diseases 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000035924 thermogenesis Effects 0.000 description 1
- 230000000476 thermogenic effect Effects 0.000 description 1
- 238000001931 thermography Methods 0.000 description 1
- 208000013818 thyroid gland medullary carcinoma Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
提供了粪肠球菌在制备用于预防或治疗代谢综合征或用于改善机体能量的产品中的用途，所述产品为药物、食品、保健品或食品添加剂。还提供了所述粪肠球菌用于预防或治疗代谢综合征或用于改善机体能量的方法。
Description
PCT国内申请，说明书已公开。
Claims (10)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2018/114132 WO2020093237A1 (zh) | 2018-11-06 | 2018-11-06 | 粪肠球菌的用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113164530A true CN113164530A (zh) | 2021-07-23 |
Family
ID=70610757
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880099068.6A Pending CN113164530A (zh) | 2018-11-06 | 2018-11-06 | 粪肠球菌的用途 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN113164530A (zh) |
| WO (1) | WO2020093237A1 (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114042091A (zh) * | 2021-10-24 | 2022-02-15 | 郑州大学 | 酪黄肠球菌在制备治疗代谢综合征产品中的应用方法 |
| WO2023153903A1 (ko) * | 2022-02-11 | 2023-08-17 | 연세대학교 원주산학협력단 | 엔테로코커스 패칼리스, 이의 배양액 또는 이의 사균체를 유효성분으로 포함하는 지방간 예방 또는 치료용 조성물 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112451564A (zh) * | 2020-04-13 | 2021-03-09 | 延边大学 | 草苁蓉提取物在制备用于预防和/或治疗代谢综合征，或者改善机体能量代谢的药物、食品或保健品中的应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110053112A (ko) * | 2009-11-13 | 2011-05-19 | 한국식품연구원 | 신규한 엔테로코커스 패칼리스 케이-60 균주 및 상기 균주를 이용한 포도당 항상성 개선용 인삼 발효 추출물 및 이의 제조방법 |
| KR101508586B1 (ko) * | 2013-10-21 | 2015-04-08 | 한국식품연구원 | 비만억제능이 우수한 신규한 엔테로코커스 휘칼리스 md366 균주 |
| CN108159084A (zh) * | 2018-01-09 | 2018-06-15 | 东北农业大学 | 一种具有降血脂作用的粪肠球菌和菊粉复合物及其制法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103371273A (zh) * | 2012-04-13 | 2013-10-30 | 蒋爱国 | 一种禽畜肉质风味改良剂 |
| CN107903310B (zh) * | 2017-11-16 | 2021-02-05 | 广州佰斯伦生物技术有限公司 | 一种重组膜蛋白、微生物、含有其的组合物及应用 |
-
2018
- 2018-11-06 CN CN201880099068.6A patent/CN113164530A/zh active Pending
- 2018-11-06 WO PCT/CN2018/114132 patent/WO2020093237A1/zh active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110053112A (ko) * | 2009-11-13 | 2011-05-19 | 한국식품연구원 | 신규한 엔테로코커스 패칼리스 케이-60 균주 및 상기 균주를 이용한 포도당 항상성 개선용 인삼 발효 추출물 및 이의 제조방법 |
| KR101508586B1 (ko) * | 2013-10-21 | 2015-04-08 | 한국식품연구원 | 비만억제능이 우수한 신규한 엔테로코커스 휘칼리스 md366 균주 |
| CN108159084A (zh) * | 2018-01-09 | 2018-06-15 | 东北农业大学 | 一种具有降血脂作用的粪肠球菌和菊粉复合物及其制法 |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114042091A (zh) * | 2021-10-24 | 2022-02-15 | 郑州大学 | 酪黄肠球菌在制备治疗代谢综合征产品中的应用方法 |
| WO2023153903A1 (ko) * | 2022-02-11 | 2023-08-17 | 연세대학교 원주산학협력단 | 엔테로코커스 패칼리스, 이의 배양액 또는 이의 사균체를 유효성분으로 포함하는 지방간 예방 또는 치료용 조성물 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020093237A1 (zh) | 2020-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9750775B2 (en) | Lactic acid bacterium-containing preparation | |
| EP2123168A1 (en) | Lactobacillus paracasei and weight control | |
| CN112716982B (zh) | 含乳酸菌的组合物及其用途 | |
| JP5592640B2 (ja) | 乳酸菌発酵ローヤルゼリーを含有する抗ストレス剤、その製造方法、視床下部−下垂体−副腎皮質系の活動抑制剤、及び交感神経−副腎髄質系の活動抑制剤 | |
| AU2019241546B2 (en) | Sleep-promoting composition, and medicinal composition and food and beverage composition using said sleep-promoting composition | |
| CN113164530A (zh) | 粪肠球菌的用途 | |
| CN112980725B (zh) | 一种乳双歧杆菌及其在促进儿童青少年生长发育中的用途 | |
| US20170252381A1 (en) | Uses of bacteroides in treatment or prevention of obesity and obesity-related diseases | |
| JP6793380B2 (ja) | スクロース摂取による血糖値上昇を抑制する物質の評価方法、スクリーニング方法及び製造方法 | |
| JP2019112328A (ja) | 概日リズム改善用組成物 | |
| CN109999019B (zh) | 肉豆蔻脑酸甲酯在制备预防或治疗代谢综合征或改善机体能量代谢的产品中的应用 | |
| JP6571298B2 (ja) | 血糖値スパイク抑制剤、食品及び血糖値スパイク抑制剤の製造方法 | |
| CN116376740A (zh) | 一株具有降血糖功效的长双歧杆菌及其应用 | |
| JP7149427B2 (ja) | 学童期の記憶能向上のための乳幼児用組成物 | |
| CN115651854A (zh) | 一种植物乳杆菌yg06菌株及其应用 | |
| JP7266580B2 (ja) | 学童期以降の高血糖に起因する疾患の予防のための乳幼児用組成物 | |
| CN115551365A (zh) | 睡眠促进用组合物、和包含组合物的食品、药物、和饲料 | |
| CN112654358A (zh) | 用于缓解肠易激综合征和用于缓解其它胃肠道疾病的乳酸杆菌组合 | |
| CN111345345A (zh) | 戊糖片球菌的用途 | |
| JP7402629B2 (ja) | プロピオン酸菌発酵物含有組成物 | |
| WO2024055983A1 (zh) | 南瓜籽蛋白组合物和其应用 | |
| WO2020177094A1 (zh) | 肉豆蔻脑酸甲酯在制备预防或治疗代谢综合征或改善机体能量代谢的产品中的应用 | |
| JP6785141B2 (ja) | 基礎代謝亢進剤 | |
| Surendran et al. | Role of Synbiotics in Gastrointestinal Disorders | |
| CA3214541A1 (en) | Compositions and methods using a combination of at least one fiber and at least one probiotic to improve microbiome resilience |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210723 |